Autobahn Speeds Lead Drug Into Phase II With $100m In Fresh Cash

Second Candidate Headed For Phase I In 2025

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Autobahn raised $100m in series C venture capital to take its oral, brain-penetrant thyromimetic ABX-002 into Phase II studies in major depressive disorder and bipolar disorder depression.

Neon sign shaped like a brain
Autobahn is developing brain-penetrant oral drugs • Source: Shutterstock

Autobahn Therapeutics wanted to take advantage of the neuropsychiatric benefits observed with thyroid hormone therapy without systemic side effects, so the company used its proprietary technology for oral drugs that can cross the blood-brain barrier to develop a thyromimetic as an adjunctive treatment for depression. Now, with $100m in series C venture capital in hand, Autobahn plans to initiate Phase II clinical trials later this year for lead drug candidate ABX-002.

Key Takeaways

  • Autobahn Therapeutics raised a $100m series C venture capital round to take lead drug candidate ABX-002 into Phase II clinical trials this year in major depressive disorder and bipolar depression.

President and CEO Kevin Finney told Scrip that the company, which announced its series C round on 24 July, plans...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.